← Eichor
Study identifier: NCT06028737 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer

Condition: Gastric Cancer · Stomach Cancer · GastroEsophageal Cancer  ·  Sponsor: Ukrainian Society of Clinical Oncology

PhasePhase 2/Phase 3
Planned participants150
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

The main goal of this study is to investigate the proportion of participants with locally advanced gastric and gastroesophageal adenocarcinoma without previous treatment during the last 5 years who can tolerate all planned cycles of chemotherapy and radical surgical treatment who will be prospectively randomized into two groups to undergo one of two chemotherapy regimens, followed by surgery: 1. 8 cycles of Total Neoadjuvant ChemoTherapy (TNT) with 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin, and Docetaxel (FLOT) followed by surgery. 2. 4 cycles of Neoadjuvant FLOT chemotherapy scheme preoperatively and 4 adjuvant FLOT cycles postoperatively.

This description comes directly from the study's public registry record.

Talk to the study team

Mykyta Pepenin, MD  ·  +380959448858  ·  pepenin95@gmail.com

Oleksii Dobrzhanksiy, MD  ·  +380638760185  ·  alekseydobrzhanskiy@gmail.com

Always discuss trial participation with your own doctor first.

Locations (2)

National Cancer InstituteVilnius, LithuaniaRecruiting
National Cancer InstituteKyiv, UkraineRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06028737